The role of morphine glucuronides in cancer pain

Palliative Medicine

Volumn 13, Issue 2, 1999, Pages 95-104

  Mercadant, Sebastiano ^a  

^a SAMOT Onlus   (Italy)

Author keywords

Drug toxicity; Morphine; Neoplasms; Pain

Indexed keywords

DRUG METABOLITE; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE;

AGITATION; ALLODYNIA; CANCER PAIN; DELIRIUM; DROWSINESS; DRUG METABOLISM; EPIDURAL DRUG ADMINISTRATION; HUMAN; HYPERALGESIA; INTRATHECAL DRUG ADMINISTRATION; KIDNEY FAILURE; MYOCLONUS; NAUSEA; ORAL DRUG ADMINISTRATION; RECTAL DRUG ADMINISTRATION; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; VOMITING;

ANALGESICS, OPIOID; HUMANS; MORPHINE; MORPHINE DERIVATIVES; NEOPLASMS; PAIN;

EID: 0032939615     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1191/026921699678158579     Document Type: Review

References (77)

1. Hanks GW, De Conno F, Ripamonti C et al. Morphine in cancer pain: modes of administration. Br Med J 1996; 312: 826-28.
2. Faura CC, Moore RA, Horga JF, Hand CW, McQuay HJ. Morphine and morphine-6-glucuronide plasma concentrations and effects in cancer pain. J Pain Symptom Manage 1996; 11: 95-102.
3. McQuay HJ, Carroll D, Faura CC, Cavaghan DJ, Hand CW, Moore RA. Oral morphine in cancer pain: influence on morphine and metabolite concentration. Clin Pharmacol Ther 1990; 48: 236-44.
4. Osborne R, Joel S, Trew D, Slevin M. Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 1990; 47: 12-19.
5. Sawe J. High-dose morphine and methadone in cancer patients: clinical considerations of oral treatment. Clin Pharmacokin 1986; 11: 87-106.
6. Hanna MH, Peat SJ, Woodham M, Knibb A, Fung C. Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. Br J Anaesth 1990; 64: 547-50.
7. Kalman S, Metcalf K, Eintrei C. Morphine, morphine-6-glucuronide, and morphine-3-glucuronide in cerebrospinal fluid and plasma after epidural administration of morphine. Reg Anesth 1997; 22: 131-36.
8. Warren DE. Practical use of rectal medications in palliative care. J Pain Symptom Manage 1996; 11: 378-87.
9. Tiseo PJ, Thaler HT, Lapin J, Inturrisi CH, Portenoy RK, Foley KM. Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain 1995; 61: 47-54.
10. Peterson GM, Randall CTC, Paterson J. Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration. Eur J Clin Pharmacol 1990; 38: 121-24.
11. Babul N, Darke AC. Disposition of morphine and its glucuronide metabolites after oral and rectal administration: evidence of route specificity. Clin Pharmacol Ther 1993; 54: 286-92.
12. Portenoy RK, Foley KM, Stulman J et al. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain 1991; 47: 13-19.
13. Osborne RJ, Joel SP, Slevin ML. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J 1986; 292: 1548-49.
14. Gourlay GK, Plummer JL, Cherry DA. Chronopharmacokinetic variability in plasma morphine concentrations following oral doses of morphine solution. Pain 1995; 61: 375-81.
15. Burchell B, Coughtrie WH. UDP-glucuronosyltransferases. Pharmacol Ther 1989; 43: 261-89.
16. Goucke CR, Hackett LP, Ilett KF. Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine-resistant pain. Pain 1994; 56: 145-49.
17. Hunt A, Joel S, Cloyne A, Goldman A. Establishing pharmacokinetic parameters of oral morphine and its glucuronides in children with cancer. Eighth world congress on pain. Vancouver: 17-22 August 1996: 394.
18. Van Crutgen JT, Somogyi AA, Nation RL, Reynolds G. The effect of old age on the disposition and nociceptive response of morphine and morphine-6-glucuronide in the rat. Pain 1997; 71: 199-205.
19. Wahlstrom A, Pacifici GM, Lindstrom B, Hammar L, Rane A. Human liver morphine UDP-glucuronyl transferase enantioselectivity and inhibition by opioid congeners and diazepam. Br J Pharmacol 1988; 94: 864-70.
20. Osborne R, Joel S, Trew D, Slevin M. Analgesic activity of morphine-6-glucuronide. Lancet 1988; i: 828.
21. D'Honneur G, Gilton A, Sandouk P, Schermann JM, Duvaldestin P. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine. The influence of renal failure. Anaesthesiology 1994; 81: 87-93.
22. Elston AC, Bayliss MK, Park GR. Effect of renal failure on drug metabolism by the liver. Br J Anaesth 1993; 71: 282-90.
23. Kaiko RK, Foley K, Grabinski PY et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neural 1983; 13: 150-85.
24. Osborne R, Joel S, Grebenik K, Trew D, Slevin M. The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther 1993; 54: 158-67.
25. Jones N, Durcan T, Fung M et al. The effect of age and type of surgery on the pharmacokinetics of morphine and its active metabolite morphine-6-glucuronide. Eighth world congress on pain. Vancouver: 17-22 August 1996: 395.
26. Calleja MA, Childs D, Venn RF, Michalkiewicz A. Persistently increased morphine-6-glucuronide concentrations. Br J Anaesth 1990; 64: 649.
27. De Stoutz ND, Bruera E, Suarez-Almozor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995; 10: 378-84.
28. Woolf T, Samuelsson H, Hedner T. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration. Pain 1995; 62: 147-54.
29. Portenoy RK, Khan E, Layman M et al. Chronic morphine therapy for cancer pain: plasma and cerebrospinal fluid morphine and morphine-6-glucuronide concentrations. Neurology 1991: 41: 1457-61.
30. Hagen NA, Foley KM, Cerbone DJ, Portenoy RK, Inturrisi CE. Chronic nausea and morphine-6-glucuronide. J Pain Sympt Manage 1991; 6: 125-28.
31. Hoskin PJ, Hanks GW, Heron CW, Aherne GW. M6G and its analgesic action in chronic use. Clin J Pain 1989; 5: 199-201.
32. Woolf T, Samuelsson H, Hedner T. Concentrations of morphine and morphine metabolites in CSF and plasma during continuous subcutaneous morphine administration in cancer pain patients. Pain 1996; 68: 209-16.
33. Poulain P, Moran Ribon A, Hanks GW, Hoskin PJ, Aherne GW, Chapman DJ. CSF concentrations of morphine-6-glucuronide after oral administration of morphine. Pain 1990; 41:115-16.
34. Geisslinger G, Brune K, Kobal G, Lotsch J. Intravenous morphine-6-glucuronide (M6G) is devoid of analgesic activity in man. Pain 1997; 70: 289-90.
35. Samuelsson H, Hedner T, Venn R, Michalkiewics A. CSF and plasma concentrations of morphine and morphine glucuronides in cancer patients receiving epidural morphine. Pain 1993; 46: 3-8.
36. Nordberg G. Pharmacokinetic aspects of spinal morphine analgesia. Acta Anesthesiol Scand 1984; 28: 1-38.
37. Samuelsson H, Nordberg G, Hedner T, Lindquist J. CSF and plasma morphine concentrations in cancer patients during chronic epidural morphine therapy and its relation to pain relief. Pain 1987; 30: 303-10.
38. Bigler D, Christensen CB, Eriksen J, Jensen NH. Morphine, morphine-6-glucuronide and morphine-3-glucuronide concentrations in plasma and cerebrospinal fluid during long-term high-dose intrathecal administration. Pain 1990; 41: 15-18.
39. Frances B, Gout R, Monsarrat B, Cros J, Zajac JM. Further evidence that morphine-6-glucuronide is a more potent opioid agonist than morphine. J Pharmacol Exp Ther 1992; 262: 25-31.
40. Frances B, Gout R, Campistron G, Panconi E, Cros J. Morphine-6-glucuronide is more mu-selective and potent in analgesic tests than morphine. Progr Clin Biol Res 1990; 328: 477-80.
41. Pasternak GW, Bodnar RJ, Clark JA, Inturrisi CE. Morphine-6-glucuronide: a potent mu-agonist. Life Sci 1987; 41: 2845-49.
42. Sullivan AF, McQuay HJ, Bailey D, Dickenson AH. The spinal antinociceptive actions of morphine metabolites, morphine-6-glucuronide and normorphine, in the rat. Brain Res 1989; 482: 219-24.
43. Peat SJ, Hanna MH, Woodham M, Knibb AA, Ponte J. Morphine-6-glucuronide: effects on ventilation in normal volunteers. Pain 1991; 45: 101-104.
44. Thompson P, Hucks D, McLoughlin L, Grossman A, Rees L, Slevin M. Comparative opiate receptor affinities of morphine and its active metabolite morphine-6-glucuronide. Br J Cancer 1990; 628: 484.
45. Smith GD, Smith MT. Morphine-3-glucuronide: evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in rat. Pain 1995; 52: 51-60.
46. Gong OL, Hedner J, Bjorkman R, Hedner T. Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain 1992; 48: 249-55.
47. Labella FS, Pinsky C, Havlicek V. Morphine derivatives with diminished opiate receptor potency show enhanced central excitatory activity. Brain Res 1989; 174: 263-71.
48. Gong OL, Hedner T, Hedner J, Bjorkman R, Nordberg G. Antinociceptive and ventilatory effects of the morphine metabolites: morphine-3-glucuronide and morphine-6-glucuronide. Eur J Pharmacol 1992; 193: 47-56.
49. Smith MT, Watt JA, Cramond T. Morphine-3-glucuronide: a potent antagonist of morphine analgesia. Life Sci 1990; 47: 579-85.
50. Faura CC, Olaso MJ, Cabanes CG, Horga JF. Lack of morphine-6-glucuronide antinociception after morphine treatment. Is morphine-3-glucuronide involved? Pain 1996; 65; 25-30.
51. Lipkowski AW, Carr DB, Langlade A, Osgood PF, Szyfelbein SK. Morphine-3-glucuronide: silent regulator of morphine actions. Life Sci 1994; 55: 149-54.
52. Smith MJ, Smith G. Reply. Pain 1996; 65: 286.
53. Hewett K, Dickenson AH, McQuay HJ. Lack of effect of morphine-3-glucuronide on spinal antinociceptive actions of morphine in the rat: an electrophysiological study. Pain 1993; 53: 59-63.
54. Suzuki N, Kalso E, Rosenberg PH. Intrathecal morphine-3-glucuronide does not antagonize spinal antinociception by morphine or morphine-6-glucuronide in rats. Eur J Pharmacol 1993; 249: 247-50.
55. Kuo CK, Hanioka N, Hoshikawa Y, Oguri K, Yoshimura H. Species difference of site-selective glucuronization of morphine. J Pharmacobiodyn 1991; 14: 187-93.
56. Halliday AJ, Barlett SE, Smith MT. Quantification of the differential CNS excitatory effects of morphine-3-glucuronide (M3G) in specific regions of the rat brain. Eighth world congress on pain. Vancouver: 17-22 August 1996: 396.
57. Bartlett SE, Dodd PR, Smith MT. Pharmacology of morphine and morphine-3-glucuronide at opioid, excitatory amino acid, GABA and glycine binding sites. Pharmacol Toxicol 1994; 75: 73-81
58. Werz MA, MacDonald RL. Opiate alkaloids antagonize post-synaptic glycine and GABA responses: correlation with convulsant action. Brain Res 1982; 236: 107-19.
59. Bowsher D. Paradoxical pain. Br Med J 1993; 306: 473.
60. Morley JS, Miles JB, Bowsher D. Paradoxical pain. Lancet 1992; 340: 1045.
61. Morley JS, Watt J, Wells JC, McKibbin PE, Seabra L, Miles JB. Paradoxical and other pain uncontrolled by morphine. In: Gebhart GK, Hammond DL, Jensen TS eds. Proceedings of the seventh world congress on pain. Progress in pain research and management. Vol. 2. Seattle, WA: IASP Press, 1994: 621-30.
62. Parris WCV, Janicki PK, Johnson B, Livengood J, Mathews L. Persistent pain associated with long-term intrathecal morphine administration. South Med J 1996; 89: 417-19.
63. Samuelsson H, Hadner T. Pain characterisation in cancer patients and analgesic response to epidural morphine. Pain 1991; 46: 3-8.
64. Cramond T, Stuart G. Intraventricular morphine for intractable pain of advanced cancer. J Pain Symptom Manage 1993; 8: 465-73.
65. Cramond T, Wright AWE, Stuart GS, Smith M. Plasma and CSF concentrations of morphine, M3G and M6G in cancer patients receiving morphine by intracerebroventricular route. Seventh world congress onpain. Paris: 1993: 531.
66. Bruera E, Pereira J. Neuropsychiatric toxicity of opioids. In: Jensen TS, Turner JA, WiesenfeldHallin Z eds. Proceedings of the eighth world congress on pain. Progress in pain research and management. Vol. 8. Seattle, WA: IASP Press, 1997: 717-38.
67. Sawe J, Svennson JO, Odar-Cederlof I. Kinetics of morphine in patients with renal failure. Lancet 1985; ii: 211-13.
68. Woolf J, Bigler D, Christensen CB, Rasmussen SN, Andersen HB, Tonnesen KH. Influence of renal function on the elimination of morphine and morphine glucuronides. Eur J Clin Pharmacol 1988; 34: 353-57.
69. Woolner DF, Winter D, Frendin TJ, Begg EJ, Lynn KL, Wright GJ. Renal failure does not impair the metabolism of morphine. Br J Clin Pharmacol 1986; 22: 55-59.
70. Sjogren P, Jensen NH, Jensen TS. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting with other opioid agonists. Pain 1994; 59: 313-16.
71. Sjogren P, Jonsson T, Jensen NH, Drenck NE, Jensen TS. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain 1993; 55: 93-97.
72. De Conno F, Caraceni A, Martini C, Spoldi E, Salvetti M, Ventafridda V. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain 1991; 47: 337-39.
73. Parkinson SK, Bailey SL, Little WL, Mueller JB. Myoclonic seizure activity with chronic high-dose spinal opioid administration. Anesthesiology 1990; 72: 743-45.
74. Kloke M, Bingel U, Seeber S. Complications of spinal opioid therapy: myoclonus, spastic muscle tone and spinal jerking. Support Care Cancer 1994; 2: 249-52.
75. Appelgren L, Nordborg C, Sjoberg M, Karlsson PA, Nitescu P, Curelaru I. Spinal epidural metastasis: implications for spinal analgesia to treat refractory cancer pain. J Pain Symptom Manage 1997; 13: 25-42.
76. Potter JM, Reid DB, Shaw RJ, Hackett PP, Hickmann PE. Myoclonus associated with treatment with high doses of morphine: the role of supplemental drugs. Br Med J 1989; 299: 150-53.
77. Bruera E, Franco JJ, Maltoni M, Watanabe S, Suarez-Almazor M. Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manage 1995; 10:287-91.